The latest efficacy analysis: What is the role of aceminib?

Asciminib (Asciminib) is a new leap forward in the management of patients with chronic myelogenous leukemia, with a novel mechanism of action and increased selectivity. Its current indication addresses some ongoing needs, and its mechanism of action and nonclinical data bring new possibilities to areas where current treatments are adequate but not optimal.

Aceminibis a targeted drug used to treat chronic myelogenous leukemia (CML). It inhibits the expression of BCR-ABL fusion gene and prevents tumor cell proliferation, thereby achieving the effect of treating CML. Aceminib's unique mechanism of action enables it to act precisely on tumor cells, reducing damage to normal cells and reducing side effects during treatment.

Aximini is mainly used to treat Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+CML), patients in chronic phase (CP) who have previously received two or more tyrosine kinase inhibitors (TKIs), and Ph+CML patients in CP with T315I mutation. Compared with traditional treatment methods, Aceminib has a more precise targeting effect and can effectively inhibit the growth of leukemia cells and improve the effectiveness of treatment.

In clinical trials, aximinib has shown good safety and tolerability, and compared with bosutinib, aximinib has better efficacy in treating patients with the above types of CML The efficacy of Aceminib is mainly reflected in its ability to effectively reduce the burden of tumor cells, control disease progression, and improve patients' quality of life.

The safety profile of aceminid has been consistent across reported studies. Not surprisingly for a heavily treated patient population, myelosuppression was the most common adverse event, particularly thrombocytopenia (22.4% of patients with ASCEMBL ≥ grade 3). Among nonhematological AEs, the only grade >3 event with an incidence >5% was hypertension. Elevated lipase is also frequently observed.

It should be noted that Aceminid is a prescription drug and needs to be used under the guidance of a doctor. Patients should fully understand its indications, usage and dosage, side effects and other information before using Asiminib, so as to better cooperate with doctors for treatment. At the same time, patients should be monitored and reviewed regularly during the treatment process, and the treatment plan should be adjusted in a timely manner to achieve the best treatment effect.

The original drug of Asiminib has not yet been launched in China, so it cannot be included in the medical insurance. The original drug of Asiminib sold overseas is very expensive. The price of 20mg*60 oral tablets is about more than 20,000 US dollars, which is about 150,000 yuan in RMB. Also available overseasAcemini Generic drugs are produced and put on the market, and their drug ingredients are basically the same as those of the original drug. For example, the specifications produced by Laos Pharmaceutical Factory The price of 40mg*60 tablets per box may be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap. For more information about overseas drugs and specific prices, please consult Yaode Medical Consultant.